KZIA

Announcements

Nothing here yet

Daily updates

• Kazia Therapeutics announced that partner Sovargen initiated dosing in a Phase 1b/2a trial of paxalisib in rare seizure disorders, triggering a $2 million milestone payment and expanding the program beyond oncology.Sep 22, 2026

FDA designations

Nothing here yet

News

• Kazia Therapeutics announces first patient dosed in a Phase 1b/2a paxalisib trial for rare seizure disordersSep 22, 2026
• Kazia Therapeutics files provisional patent for a strategy to prevent metastatic recurrence in triple-negative breast cancerJul 28, 2026
• Kazia Therapeutics expands ongoing Phase 1b trial of paxalisib in advanced breast cancerMay 26, 2026
• Kazia Therapeutics highlights new clinical and translational data showing Paxalisib reinvigorates anti-tumor immunity across advanced breast cancer, including TNBC and HER2+Dec 10, 2025
• Kazia Therapeutics achieved initial immune-complete response (iCR) in metastatic triple-negative breast cancer and delivered Q4 business update with breakthroughs across breast cancer, immuno-oncology, and GBM regulatory strategyNov 19, 2025